STENOCARE approved to supply Danish patients with new CBD medical cannabis oil product

STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO STENOCARE A/S (“STENOCARE”) hereby announces that it has received approval from The Danish Medicines Agency to sell a new CBD medical cannabis oil product to Danish patients. With this, STENOCARE once again becomes the only supplier of both CBD and THC medical cannabis oil products under the Danish Pilot Programme.

STENOCARE is a supplier of prescription-based medical cannabis products for patients’ treatment. The company has experience delivering prescription-based products for patients in Denmark, Sweden, and the UK, and now enters the Danish market with a new CBD medical cannabis oil product.

The product is called “CBD Olie STENOCARE” and contains 20 mg/mL CBD. The new product has been examined by The Danish Medicines Agency for compliance with the Danish Pilot Programme and its strict quality standards. After a very thorough process, the product has now been accepted into the Danish program.

The new product from STENOCARE becomes the second oil product available for patients under the Programme in Denmark – where both products are supplied by Stenocare. It is expected that the new product will be available for patients during Q4 2022 pending international import and export certificates.  

Thomas Skovlund Schnegelsberg, CEO of STENOCARE is commenting:

“This announcement is a big deal for Stenocare and Denmark. We are proud to be the only supplier of both CBD and THC oil for the Danish Pilot Programme, and it is highlighting the capabilities of our regulatory team to work with the Danish Medicines Agency to meet the strict requirements for quality and standardization compliance”.